<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04178850</url>
  </required_header>
  <id_info>
    <org_study_id>GENOR GB242-002</org_study_id>
    <nct_id>NCT04178850</nct_id>
  </id_info>
  <brief_title>Clinical Comparative Study to Evaluate the Efficacy and Safety of Recombinant Anti-TNF-alpha Antibodies for Injection</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center Phase Ⅲ Comparative Study to Evaluate the Efficacy and Safety of Recombinant Human-mouse Chimeric Anti-TNF-alpha Monoclonal Antibody for Injection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genor Biopharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genor Biopharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the similarity of the proportion of subjects who achieved ACR20 at week
      30 in the two groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2017</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with ACR20</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>Number of Participants with ACR20</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with ACR50</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>Number of Participants with ACR50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with ACR70</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>Number of Participants with ACR70</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with DAS28</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>Number of Participants with DAS28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibody, ADA</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>Anti-Drug Antibody, ADA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC τ</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>AUC τ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C min,ss</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>C min,ss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C max,ss</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>C max,ss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C av,ss</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>C av,ss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T 1/2</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>T 1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL ss /F</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>CL ss /F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effect, AE</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>Adverse Effect, AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Efect, SAE</measure>
    <time_frame>Up to 30 weeks.</time_frame>
    <description>Serious Adverse Efect, SAE</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">568</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>GB242</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infliximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GB242</intervention_name>
    <description>GB242: Dosing of 3 mg/kg, intravenous drip, to be completed over 120 minutes, dosing at weeks 0, 2, 6, 14 and 22, a total of 5 doses; MTX:Dosage and administration at enrollment are maintained (10~15mg/week), oral administration, a total of 30 doses; Folic acid: 5-10mg/week, oral administration, a total of 30 doses</description>
    <arm_group_label>GB242</arm_group_label>
    <other_name>MTX</other_name>
    <other_name>Folic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Infliximab: Dosing of 3 mg/kg, intravenous drip, to be completed over 120 minutes, dosing at weeks 0, 2, 6, 14 and 22, a total of 5 doses; MTX:Dosage and administration at enrollment are maintained (10~15mg/week), oral administration, a total of 30 doses; Folic acid: 5-10mg/week, oral administration, a total of 30 doses</description>
    <arm_group_label>Infliximab</arm_group_label>
    <other_name>MTX</other_name>
    <other_name>Folic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18 to 75 years, males or females;

          2. Subjects who have confirmed rheumatoid arthritis for at least 3 months according to
             2010 American College of Rheumatology Classification Criteria (amendment);

          3. The active stage is met at screening: the following 3 items should be met (based on 28
             joints):

             Swelling of 4 or more joints; tenderness of 6 or more joints; Tenderness of 6 or more
             joints; At least one of the following criteria is met: erythrocyte sedimentation rate
             &gt;28mm/h or C-reactive protein &gt;10mg/L (1mg/dl);

          4. Subjects who have been treated with MTX treatment for at least 3 months before the
             before the use of invesetigational products and the dose remains stable (10~15mg/week)
             for at least 4 weeks;

          5. The following DMARDs except MTX (including but not limited to chloroquine,
             hydroxychloroquine, gold preparation, penicillamine, sulfasalazine, azathioprine,
             cyclophosphamide, cyclosporin A, glucosinolate, auranofin etc.) are discontinued at
             least 4 weeks before the use of invesetigational products. Should any leflunomide is
             previously used, the subjects can be enrolled after 4 weeks after washout with
             cholestyramine (8g, three times per day) for 11 days. If leflunomide is discontinued
             12 weeks ago, the patients can be enrolled without washout with cholestyramine.

          6. If glucocorticoids are being administered before the use of invesetigational products,
             the dose must be stable and remains ≤10mg/d (equivalent to the dose of prednisone) for
             at least 4 weeks; if no glucocorticoids is used, no oral administration is given at
             least 4 weeks ago or no local injection is given at least 12 weeks ago.

          7. The Chinese traditional patent medicine or Chinese herbal medicine for RA treatment,
             physical therapy, inoculation with live (attenuated) viral/ bacterial vaccines, or
             intravenous injection of immunoglobulin (IgG) should be discontinued at least 4 weeks
             before the use of the use of invesetigational products;

          8. If other biological preparations are used, or the subjects participated in clinical
             trials of other investigational products or marketed drugs before the use of
             invesetigational products, an interval of at least 3 months is required.

          9. Female patients of child-bearing potential have negative pregnancy test at screening;
             both males and females agree to adopt medically confirmed effective contraceptive
             measures during the entire study period and within 6 months after the end of this
             study.

         10. Voluntarily participate in the clinical trial and sign the informed consent form;

         11. Be able to understand and complete assessment forms;

         12. Patients can well communicate with the investigators and complete the study as
             required by the study.

        Exclusion Criteria:

          1. The subjects received similar biological preparations (TNF inhibitors) for RA
             treatment within 3 months before randomization or were treated with TNF inhibitors 3
             months ago, which are assessed as ineffective by the investigator.

          2. Be allergic to any exicipent of the investigational products or any other murine or
             human-derived protein, hypersensitivity to immunoglobulin products, known to have
             medical history of allergic diseases or allergic constitution;

          3. Body weight &gt;100kg;

          4. Subjects with rheumatoid arthritis with joint function classification of grade IV or
             subjects who combined to chair or bed (refer to appendix 9 for details of joint
             function classification);

          5. Treatment with interferon within 4 weeks before the use of invesetigational products;

          6. Any of the following is positive: hepatitis B surface antigen (HBsAg), hepatitis C
             antibody (HCV-Ab), acquired immunodeficiency syndrome antibody (Anti-HIV) and
             anti-treponema pallidum antibody (TP-Ab);

          7. Patients with known tuberculosis infection and patients with high risks for
             tuberculosis infection should be excluded. If patients with latent tuberculosis
             infection (LTBI) agree to receive preventive anti-tuberculosis therapies (appendix 5)
             during the study period, they can be enrolled. Or, they will be excluded.1) Known
             tuberculosis infection (any of the following criteria is met):

             A. Active tuberculosis infection or presence of clinical signs and symptoms of
             suspected tuberculosis (pulmonary or extrapulmonary);B. Presence of active
             tuberculosis infection involved any organ system, or symptoms of other organ systems
             corresponding to tuberculosis infection;C. The radiology test or other imaging tests
             showing evidence of previous infection at screening or within the previous 3 months
             (obsolete tuberculosis evidence: scars of lung and/or pleural fiber; calcification of
             apex of lung or other sites; pulmonary hilus and /or mediastinal lymph node lesions;
             decreased volume of upper lobe of lung; pulmonary cavity).2) High risks for
             tuberculosis infection (any of the following criteria is met): A. Known to be in close
             contact with active tuberculosis patients within 3 months before screening; B.
             Subjects with low immunologic function and with evidence showing any latent
             tuberculosis infection (LTBI); C. Long stay with individuals infected with
             tuberculosis or long stay in medical service environment or institutions with high
             risks for tuberculosis transmission and infection;3) If patients with latent
             tuberculosis infection (LTBI) agree to receive preventive anti-tuberculosis therapies
             (appendix 5) during the study period, they can be enrolled. Or, they will be excluded.

             LTBI is defined as no evidence showing signs or symptoms of tuberculosis infection or
             abnormal physical examination, and chest X-ray test (other imaging tests) results
             showing no evidence of tuberculosis infection, however, interferon gamma release assay
             (IGRA) is positive or the results of two IGRA tests are not clear;

          8. Previous opportunistic infection (herpes zoster, cytomegalovirus, mycoplasma,
             pneumocystis carinii, histoplasma capsulatum, candida, aspergillus, mycobacterium
             other than mycobacterium tuberculosis etc.) within 6 months before screening;

          9. Medical history of chronic infection (e.g., chronic hepatitis, chronic renal infection
             etc.), serious or life-threatening infection (e.g., hepatitis, pneumonitis and
             pyelonephritis etc.) or any current symptoms or signs indicating possible presence of
             infection (e.g., pyrexia, cough, urgent micturition, urodynia, abdominal pain,
             diarrhea, cutaneous infected wound etc.)

         10. Patients who are in high risk for infection (e.g., leg ulcer, retention
             catheterization, persistent or recurrent chest infection and bedridden or
             wheelchair-bound for a long term);

         11. Medical history of lymphoproliferative disorder (including lymphoma, or signs or
             symptoms reflecting lymphoproliferative disorders at any time); or splenomegaly;

         12. Patients who previously or currently have malignant tumors within 5 years before
             screening (excluding adequately treated and completely cured skin basal cell carcinoma
             or squamous cell carcinoma, cervical in situ carcinoma);

         13. Current or previous presence of congestive heart failure or medical history of
             congestive heart failure;

         14. Current presence of interstitial lung disease or medical history of previous
             interstitial lung disease;

         15. Current or previous presence of multiple sclerosis or other demyelinating diseases of
             the central nervous system or corresponding medical history of these diseases;

         16. There is evidence showing that the patients have serious, progressive and uncontrolled
             cardiovascular, renal, hepatic, hemopoietic, gastrointestinal, endocrine, pulmonary,
             nervous system disorders; and other conditions who are considered unsuitable for
             participating in this study at the discretion of the investigator;

         17. The following abnormal laboratory variables should be excluded: white blood cells
             (WBC) &lt;3.0×109/L, neutrophil count (ANC)&lt;1.5×109/L, platelet count (PLT) &lt;100×109/L,
             hemoglobin (HGB) &lt;85g/L, alanine aminotransferase (ALT) or aspartate aminotransferase
             (AST) &gt; 2 times the upper limit of normal (ULN), alkaline phosphatase (ALP)&gt; 2 times
             the upper limit of normal (ULN), serum creatinine (Cr) &gt; 1.5 times ULN;

         18. Current or previous presence of other systemic immune diseases (e.g., systemic lupus
             erythematosus etc.), or inflammatory joint disease other than rheumatoid arthritis
             (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy
             and Lyme disease etc.); Patients with rheumatoid arthritis complicated with secondary
             Sjogren syndrome which will not affect drug evaluation at the discretion of the
             investigator are allowed to be enrolled.

         19. Subjects with medical history of prosthetic joint infection and the artificial joints
             are still in the body;

         20. Subjects who received arthroplasty for more than 3 times;

         21. Subjects who received organ transplantation within 6 months before screening;

         22. Lactating women;

         23. Subjects who have medical history of long-term alcohol abuse or drug abuse;

         24. Subjects who have insufficient communication, understanding and cooperation, or
             subjects who have low education level, cannot understand and correctly complete
             corresponding forms, subjects who have history of noncompliance with doctor's
             instructions to receive administration, or subjects who have other conditions which
             may interfere with protocol compliance of subjects (e.g., subjects who have
             psychiatric disorders or usually travel, and lack of motivation to participate in the
             study);

         25. Subjects who have other diseases (e.g., clinically significant symptoms or abnormal
             laboratory variables) which are considered unsuitable for participating in this
             clinical study at the discretion of the investigator; This study allows repeated
             screening at screening. The most recent test results prior to the first dose of all
             items are regarded as the baseline values.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhanguo Li, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shawn Yu, Master</last_name>
    <phone>010-65260820</phone>
    <email>Shawn.Yu@genorbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University People Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhanguo Li, Ph.D</last_name>
      <phone>010-88324173</phone>
      <email>zgli99@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

